Cerebral Venous Thrombosis 

  • Author: W Alvin McElveen, MD; Chief Editor: Helmi L Lutsep, MD   more...
 
Updated: May 16, 2012
 

Background

Thrombosis of the venous channels in the brain is an uncommon cause of cerebral infarction relative to arterial disease, but it is an important consideration because of its potential morbidity. (See Prognosis.)

Knowledge of the anatomy of the venous system is essential in evaluating patients with cerebral venous thrombosis (CVT), since symptoms associated with the condition are related to the area of thrombosis. For example, cerebral infarction may occur with cortical vein or sagittal sinus thrombosis secondary to tissue congestion with obstruction. (See Presentation.)

Lateral sinus thrombosis may be associated with headache and a pseudotumor cerebri–like picture. Extension into the jugular bulb may cause jugular foramen syndrome, while cranial nerve palsies may be seen in cavernous sinus thrombosis as a compressive phenomenon. Cerebral hemorrhage also may be a presenting feature in patients with venous sinus thrombosis. (See Presentation.)

Imaging procedures have led to easier recognition of venous sinus thrombosis (see the images below), offering the opportunity for early therapeutic measures. (See Workup.)

Left lateral sinus thrombosis demonstrated on magnLeft lateral sinus thrombosis demonstrated on magnetic resonance venography (MRV). This 42-year-old woman presented with sudden onset of headache. Physical examination revealed no neurologic abnormalities. Axial view of magnetic resonance (MR) venogram demAxial view of magnetic resonance (MR) venogram demonstrating lack of flow in transverse sinus.
Next

Etiology

Many causative conditions have been described in cerebral venous thrombosis (CVT). These may be seen alone or in combination. For example, a prothrombin gene mutation in association with oral contraceptive use raises the odds ratio for developing CVT.

Sinusitis

Infection may occur by extension from the paranasal sinuses. These cases also may be associated with subdural empyema. Bacterial meningitis as a coexistent condition should be considered in these cases. Frontal sinuses are the most common source of infection, with spread through the emissary veins between the posterior sinus mucosa and the meninges. Rarely, sphenoid sinusitis may be associated with cavernous sinus thrombosis. Multiple organisms are to be considered, Staphylococcus aureus being the most common. In chronic infections, gram-negative organisms and fungi such as Aspergillus species may be found.

Trauma and surgery

Trauma may also be an etiologic event. Cerebral sinus thrombosis easily may be overlooked in cases of minor head trauma. Neurosurgical procedures such as dural taps and infusions into the internal jugular vein have been implicated as well.

Hypercoagulable states

Many medical conditions have been associated with CVT. For example, hypercoagulable states associated with the antiphospholipid syndrome, protein S and C deficiencies, antithrombin III deficiency, lupus anticoagulant, and the Leiden factor V mutation may result in CVT. Antibodies against the fibrinolytic receptor, annexin A2 (titer >3 standard deviations), are significantly associated with CVT.[1] Pregnancy also is associated with a hypercoagulable tendency. Malignancies may be associated with hypercoagulable states as well, and therefore may be risk factors.

Intracranial hypotension

Isolated cortical venous thrombosis has been associated with intracranial hypotension syndrome, but only rarely. In a study, Schievink and Maya found that CVT was present in only 3 (2.1%) out of 141 patients with spontaneous intracranial hypotension.[2]

Lumbar puncture

A few cases of CVT have been reported after lumbar puncture (LP), suggesting a causal association. In a study by Canhao et al, LP induced a sustained decrease in mean blood flow velocity (BFV) in the straight sinus (SS), suggesting that the decrease in venous blood flow is a possible mechanism contributing to the occurrence of CVT. In the study, the investigators used transcranial Doppler ultrasonography to register the mean BFV of the SS before, during, and after LP. LP induced a decrease of 47% in mean BFV in the SS, with the mean decrease being significant immediately at the end, 30 min after, and more than 6 hours after LP.[3]

Medications

Several medications are reported to increase the risk of CVT, including the following:

  • Oral contraceptives - Including the third-generation formulations
  • Corticosteroids
  • Epsilon-aminocaproic acid
  • Thalidomide
  • Tamoxifen
  • Erythropoietin
  • Phytoestrogens
  • L-asparaginase
  • Heparin - Heparin therapy has been reported to produce thrombotic thrombocytopenia with associated venous sinus thrombosis

Additional disease risk factors

Other diseases that have been described as risk factors for CVT include the following:

  • Inflammatory bowel diseases, such as Crohn disease and ulcerative colitis, are described as risk factors for venous thrombosis[4] ; corticosteroids used in treatment of these conditions may play a causative role
  • Pregnancy and puerperium are important considerations in women of childbearing age
  • Hematologic conditions, including paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura, sickle cell disease, and polycythemia, are to be considered
  • Collagen-vascular diseases, such as systemic lupus erythematosus, Wegener granulomatosis, and Behçet syndrome, have been reported to be associated with CVT
  • Hyperhomocysteinemia is a strong and independent risk factor for CVT, being present in 27-43% of patients with CVT but in only 8-10% of the general population; whether treatment with folate, pyridoxine, and/or cobalamin reduces the risk of CVT is unclear
  • Dehydration
  • Spontaneous intracranial hypotension
  • High altitude
  • Hepatic cirrhosis
Previous
Next

Epidemiology

International occurrence

The incidence of cerebral venous thrombosis (CVT) is difficult to determine, but generally, it is believed to be an uncommon cause of stroke, with the reported ratio of venous to arterial strokes being 1:62.5. In 1973, Towbin reported CVT in 9% of 182 autopsies,[5] while in 1995, Daif reported a frequency in Saudi Arabia of 7 cases per 100,000 hospital patients.[6]

However, with the advent of newer imaging techniques, the reported incidence of CVT is likely to increase as less severe cases are found.

Sex- and age-related demographics

CVT is believed to be more common in women than in men. In a series of 110 cases, Ameri and Bousser found a female-to-male ratio of 1.29:1.[7]

In 1992, Ameri and Bousser reported a uniform age distribution in men with CVT, while 61% of women with CVT were aged 20-35 years.[7] This difference may be related to pregnancy or the use of oral contraceptives.[8]

Previous
Next

Prognosis

Smith demonstrated the efficacy of anticoagulant and thrombolytic therapy in patients with cerebral venous thrombosis (CVT). In his study, he compared outcomes of patients who were treated with heparin and local infusion of urokinase (12 patients) with those of patients who received no treatment (21 patients).[9] The results appear in the Table, below.

Table. Patients With Cerebral Venous Thrombosis Treated With Heparin and Local Infusion of Urokinase vs Nontreated Group (Open Table in a new window)

Treated Group, % (n = 12) Nontreated Group, % (n = 21)
Full recovery62.529
Mild disability12.513
Severe disability12.59.6
Fatal outcome12.548

Morbidity and mortality

Herniation attributable to unilateral mass effect is the major cause of death in CVT. In CVT patients with large parenchymal lesions causing herniation, decompressive surgery has been lifesaving and often results in good functional outcome, even in patients with severe clinical conditions.[10]

Mortality in untreated cases of venous thrombosis has been reported to range from 13.8-48%; this high mortality rate may be a reflection of clinical severity at entrance into the study. Between 25% and 30% of patients have full recovery.

In a Portuguese study that prospectively analyzed 91 patients with CVT over a mean 1-year follow-up interval, the majority of patients experienced complete recovery.[11] Of the patients analyzed, 7% died in the acute phase, 1% died during the one year follow-up, 82% recovered completely, and 1% were dependent; 59% developed thrombotic events during the follow-up, 10% had seizures, 11% complained of severe headaches, and 1 patient experienced severe visual loss.

In 2003, Buccino et al found a good overall outcome in their reinvestigation of a series of 34 patients with confirmed CVT.[12] However, 10 patients (30%) had episodic headaches, 3 patients (8.8%) had seizures, 4 patients (11.7%) had pyramidal signs, and 2 (5.9%) had visual deficits. Mild nonfluent aphasia was seen in 3 patients. Working memory deficit and depression of mood were seen in 6 patients (17.6%).

Previous
 
 
Contributor Information and Disclosures
Author

W Alvin McElveen, MD  Director, Stroke Unit, Lakewood Ranch Medical Center; Neurologist, Manatee Memorial Hospital

W Alvin McElveen, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Neuroimaging, American Stroke Association, and Southern Clinical Neurological Society

Disclosure: Nothing to disclose.

Coauthor(s)

Andrew P Keegan, MD  Private Practice, Bradenton Neurology, Inc; Consulting Staff, Department of Neurology, Manatee Memorial Hospital, Lakewood Ranch Medical Center, Blake Medical Center

Andrew P Keegan, MD is a member of the following medical societies: American Academy of Neurology and American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Helmi L Lutsep, MD  Professor and Vice Chair, Department of Neurology, Oregon Health and Science University School of Medicine; Associate Director, Oregon Stroke Center

Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association

Disclosure: Co-Axia Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Concentric Medical Consulting fee Review panel membership

Additional Contributors

Ralph F Gonzalez, MD Private Practice, Bradenton Neurology, Inc; Consulting Staff, Department of Neurology, Blake Hospital, Lakewood Ranch Medical Center, Manatee Memorial Hospital

Ralph F Gonzalez, MD is a member of the following medical societies: American Academy of Neurology and Florida Medical Association

Disclosure: Nothing to disclose.

Howard S Kirshner, MD Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center

Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association

Disclosure: Nothing to disclose.

Norman C Reynolds Jr, MD Neurologist, Veterans Affairs Medical Center of Milwaukee; Clinical Professor, Medical College of Wisconsin

Norman C Reynolds Jr, MD is a member of the following medical societies: American Academy of Neurology, Association of Military Surgeons of the US, Movement Disorders Society, Sigma Xi, and Society for Neuroscience

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Cesarman-Maus G, Cantú-Brito C, Barinagarrementeria F, Villa R, Reyes E, Sanchez-Guerrero J. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke. Feb 2011;42(2):501-3. [Medline].

  2. Schievink WI, Maya MM. Cerebral venous thrombosis in spontaneous intracranial hypotension. Headache. Nov-Dec 2008;48(10):1511-9. [Medline]. [Full Text].

  3. Canhão P, Batista P, Falcão F. Lumbar puncture and dural sinus thrombosis--a causal or casual association?. Cerebrovasc Dis. 2005;19(1):53-6. [Medline].

  4. Ennaifer R, Moussa A, Mouelhi L, et al. Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis. Acta Gastroenterol Belg. Jul-Sep 2009;72(3):350-3. [Medline].

  5. Towbin A. The syndrome of latent cerebral venous thrombosis: its frequency and relation to age and congestive heart failure. Stroke. May-Jun 1973;4(3):419-30. [Medline].

  6. Daif A, Awada A, al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke. Jul 1995;26(7):1193-5. [Medline].

  7. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. Feb 1992;10(1):87-111. [Medline].

  8. Galarza M, Gazzeri R. Cerebral venous sinus thrombosis associated with oral contraceptives: the case for neurosurgery. Neurosurg Focus. Nov 2009;27(5):E5. [Medline].

  9. Smith AG, Cornblath WT, Deveikis JP. Local thrombolytic therapy in deep cerebral venous thrombosis. Neurology. Jun 1997;48(6):1613-9. [Medline].

  10. Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, Cucchiara B. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke. Oct 2011;42(10):2825-31. [Medline].

  11. Ferro JM, Lopes MG, Rosas MJ, et al. Long-Term Prognosis of Cerebral Vein and Dural Sinus Thrombosis. results of the venoport study. Cerebrovasc Dis. 2002;13(4):272-8. [Medline].

  12. Buccino G, Scoditti U, Patteri I, et al. Neurological and cognitive long-term outcome in patients with cerebral venous sinus thrombosis. Acta Neurol Scand. May 2003;107(5):330-5. [Medline].

  13. Flores-Barragan JM, Hernandez-Gonzalez A, Gallardo-Alcaniz MJ, Del Real-Francia MA, Vaamonde-Gamo J. [Clinical and therapeutic heterogeneity of cerebral venous thrombosis: a description of a series of 20 cases.]. Rev Neurol. Dec 1-15 2009;49(11):573-6. [Medline].

  14. Oppenheim C, Domigo V, Gauvrit JY, et al. Subarachnoid hemorrhage as the initial presentation of dural sinus thrombosis. AJNR Am J Neuroradiol. Mar 2005;26(3):614-7. [Medline].

  15. Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. May 13 2003;60(9):1418-24. [Medline].

  16. Wasay M, Kojan S, Dai AI, Bobustuc G, Sheikh Z. Headache in Cerebral Venous Thrombosis: incidence, pattern and location in 200 consecutive patients. J Headache Pain. Apr 2010;11(2):137-9. [Medline].

  17. Tardy B, Tardy-Poncet B, Viallon A, et al. D-dimer levels in patients with suspected acute cerebral venous thrombosis. Am J Med. Aug 15 2002;113(3):238-41. [Medline].

  18. Lalive PH, de Moerloose P, Lovblad K, et al. Is measurement of D-dimer useful in the diagnosis of cerebral venous thrombosis?. Neurology. Oct 28 2003;61(8):1057-60. [Medline].

  19. Kosinski CM, Mull M, Schwarz M, et al. Do normal D-dimer levels reliably exclude cerebral sinus thrombosis?. Stroke. Dec 2004;35(12):2820-5. [Medline].

  20. Ozsvath RR, Casey SO, Lustrin ES, et al. Cerebral venography: comparison of CT and MR projection venography. AJR Am J Roentgenol. Dec 1997;169(6):1699-707. [Medline].

  21. Mas JL, Meder JF, Meary E, Bousser MG. Magnetic resonance imaging in lateral sinus hypoplasia and thrombosis. Stroke. Sep 1990;21(9):1350-6. [Medline].

  22. Adams WM, Laitt RD, Beards SC, et al. Use of single-slice thick slab phase-contrast angiography for the diagnosis of dural venous sinus thrombosis. Eur Radiol. 1999;9(8):1614-9. [Medline].

  23. Ayanzen RH, Bird CR, Keller PJ, et al. Cerebral MR venography: normal anatomy and potential diagnostic pitfalls. AJNR Am J Neuroradiol. Jan 2000;21(1):74-8. [Medline].

  24. Medel R, Monteith SJ, Crowley RW, Dumont AS. A review of therapeutic strategies for the management of cerebral venous sinus thrombosis. Neurosurg Focus. Nov 2009;27(5):E6. [Medline].

  25. Bentley JN, Figueroa RE, Vender JR. From presentation to follow-up: diagnosis and treatment of cerebral venous thrombosis. Neurosurg Focus. Nov 2009;27(5):E4. [Medline].

  26. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet. Sep 7 1991;338(8767):597-600. [Medline].

  27. de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third- generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet. May 9 1998;351(9113):1404. [Medline].

  28. Rahman M, Velat GJ, Hoh BL, Mocco J. Direct thrombolysis for cerebral venous sinus thrombosis. Neurosurg Focus. Nov 2009;27(5):E7. [Medline].

  29. Ekseth K, Bostrom S, Vegfors M. Reversibility of severe sagittal sinus thrombosis with open surgical thrombectomy combined with local infusion of tissue plasminogen activator: technical case report. Neurosurgery. Oct 1998;43(4):960-5. [Medline].

  30. Alonso-Canovas A, Masjuan J, Gonzalez-Valcarcel J, et al. [Cerebral venous thrombosis: when etiology makes the difference.]. Neurologia. Sep 2009;24(7):439-45. [Medline].

  31. Benamer HT, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolyic therapy?. J Neurol Neurosurg Psychiatry. Oct 2000;69(4):427-30. [Medline].

  32. Cipri S, Gangemi A, Campolo C, et al. High-dose heparin plus warfarin administration in non-traumatic dural sinuses thrombosis. A clinical and neuroradiological study. J Neurosurg Sci. Mar 1998;42(1):23-32. [Medline].

  33. D'Alise MD, Fichtel F, Horowitz M. Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion. Surg Neurol. Apr 1998;49(4):430-5. [Medline].

  34. Davis KR, Kistler JP, Buonanno FS. Clinical neuroimaging approaches to cerebrovascular diseases. Neurol Clin. Nov 1984;2(4):655-65. [Medline].

  35. Gold Standard Multimedia. Urokinase, Altevase, Streptokinase, Heparin, Warfarin. Clinical Pharmacology. 2000;Available at:http://cp.gsm.com/. [Full Text].

  36. Gomez CR, Misra VK, Terry JB, et al. Emergency endovascular treatment of cerebral sinus thrombosis with a rheolytic catheter device. J Neuroimaging. Jul 2000;10(3):177-80. [Medline].

  37. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. Jul 15 2003;109 Suppl 1:S9-15. [Medline].

  38. Jacobs K, Moulin T, Bogousslavsky J, et al. The stroke syndrome of cortical vein thrombosis. Neurology. Aug 1996;47(2):376-82. [Medline].

  39. Leys D, Cordonnier C. Cerebral venous thrombosis: Update on clinical manifestations, diagnosis and management. Ann Indian Acad Neurol. 2008;11:79-87. [Full Text].

  40. Meyer-Lindenberg A, Quenzel EM, Bierhoff E, et al. Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia. Eur Neurol. 1997;37(3):191-2. [Medline].

  41. Zweifler RM. Management of acute stroke. South Med J. Apr 2003;96(4):380-5. [Medline].

Previous
Next
 
Left lateral sinus thrombosis demonstrated on magnetic resonance venography (MRV). This 42-year-old woman presented with sudden onset of headache. Physical examination revealed no neurologic abnormalities.
Same patient as in the previous image. One week after treatment with heparin, the magnetic resonance (MR) venogram displayed increased flow in the left lateral sinus consistent with early recanalization of the sinus; headache had resolved at this point.
Magnetic resonance venogram (MRV) - axial view; A = lateral (transverse) sinus; B = sigmoid sinus; C = confluence of sinuses; and D = superior sagittal sinus.
Magnetic resonance venogram (MRV) - sagittal view; A = lateral (transverse) sinus; C = confluence of sinuses; D = superior sagittal sinus; and E = straight sinus.
Computed tomography (CT) scan demonstrates a left posterior temporal hematoma in a 38-year-old woman on oral contraceptives (the only identified risk factor).
Contrast-enhanced magnetic resonance imaging (MRI) scan showing lack of filling of left transverse sinus.
Axial view of magnetic resonance (MR) venogram demonstrating lack of flow in transverse sinus.
Coronal view of magnetic resonance (MR) venogram demonstrating lack of flow in the left transverse and sigmoid sinuses.
Table. Patients With Cerebral Venous Thrombosis Treated With Heparin and Local Infusion of Urokinase vs Nontreated Group
Treated Group, % (n = 12) Nontreated Group, % (n = 21)
Full recovery62.529
Mild disability12.513
Severe disability12.59.6
Fatal outcome12.548
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.